Ring-Opening Polymerization of ε-Caprolactone initiated by Ganciclovir (GCV) for the preparation of GCV-tagged polymeric micelles by Sawdon, Alicia J. & Peng, Ching-An
Digital Commons @ Michigan Tech 
Michigan Technological University 
Digital Commons @ Michigan Tech 
Michigan Tech Publications 
2-10-2015 
Ring-Opening Polymerization of ε-Caprolactone initiated by 
Ganciclovir (GCV) for the preparation of GCV-tagged polymeric 
micelles 
Alicia J. Sawdon 
Michigan Technological University 
Ching-An Peng 
Michigan Technological University 
Follow this and additional works at: https://digitalcommons.mtu.edu/michigantech-p 
 Part of the Chemical Engineering Commons 
Recommended Citation 
Sawdon, A. J., & Peng, C. (2015). Ring-Opening Polymerization of ε-Caprolactone initiated by Ganciclovir 
(GCV) for the preparation of GCV-tagged polymeric micelles. Molecules, 20(2), 2857-2867. http://doi.org/
10.3390/molecules20022857 
Retrieved from: https://digitalcommons.mtu.edu/michigantech-p/1975 
Follow this and additional works at: https://digitalcommons.mtu.edu/michigantech-p 
 Part of the Chemical Engineering Commons 
Molecules 2015, 20, 2857-2867; doi:10.3390/molecules20022857 
 
molecules 
ISSN 1420-3049 
www.mdpi.com/journal/molecules 
Article 
Ring-Opening Polymerization of ε-Caprolactone Initiated by 
Ganciclovir (GCV) for the Preparation of GCV-Tagged 
Polymeric Micelles 
Alicia J. Sawdon and Ching-An Peng * 
Department of Chemical Engineering, Michigan Technological University, Houghton, MI 49931, 
USA; E-Mail: ajsawdon@mtu.edu 
* Author to whom correspondence should be addressed; E-Mail: cpeng@mtu.edu;  
Tel.: +1-906-487-2569; Fax: +1-906-487-3213. 
Academic Editor: Atsushi Sudo 
Received: 13 December 2014 / Accepted: 3 February 2015 / Published: 10 February 2015 
 
Abstract: Ganciclovir (GCV) is a nucleoside analogue with antiviral activity against 
herpes viral infections, and the most widely used antiviral to treat cytomegalovirus 
infections. However, the low bioavailability and short half-life of GCV necessitate the 
development of a carrier for sustained delivery. In this study, guanosine-based GCV was 
used as the initiator directly in ring-opening polymerization of ε-caprolactone (ε-CL) to 
form hydrophobic GCV-poly(caprolactone) (GCV-PCL) which was then grafted with 
hydrophilic chitosan to form amphiphilic copolymers for the preparation of stable micellar 
nanoparticles. Successful synthesis of GCV-PCL and GCV-PCL-chitosan were verified by 
1H-NMR analysis. Self-assembled micellar nanoparticles were characterized by dynamic 
light scattering and zetasizer with an average size of 117 nm and a positive charge of  
24.2 mV. The drug release kinetics of GCV was investigated and cytotoxicity assay 
demonstrated that GCV-tagged polymeric micelles were non-toxic. Our results showed that 
GCV could be used directly in the initiation of ring-opening polymerization of ε-CL and 
non-toxic polymeric micelles for GCV delivery can be formed. 
Keywords: chitosan; ganciclovir; poly(caprolactone); ring-opening polymerization 
 
  
OPEN ACCESS
Molecules 2015, 20 2858 
 
 
1. Introduction 
Ganciclovir (GCV), is the most widely used antiviral drug for the treatment of human 
cytomegalovirus (CMV) infections [1]. GCV however is only slightly water soluble, and as a result, 
has poor oral and ocular bioavailability. Therefore, it needs to be administered intravenously; however, 
due to its short biological half-life, frequent dosing is required, which may increase the risk of 
systemic toxicity and discomfort to the patient [1–4]. To address the aforementioned problems, several 
drug delivery systems have been developed for GCV [5–9]. Incorporation of the drug into 
nanoparticles is advantageous because a carrier can protect the drug from enzymatic degradation, 
control the drug release rate (leading to enhanced bioavailability), improve the therapeutic effects, and 
reduce administration frequency. 
In recent years, polymeric micelles have been the focus of much interest as alternative vehicles for 
the solubilization of poorly water-soluble molecules rendering clear advantages over current 
solubilizing agents in drug delivery [10]. Polymeric micelles are expected to withstand the diluting 
effect of blood, stay in a micellar form, and even act as a circulating depot drug delivery system after 
intravenous administration. Moreover, there is no inclusion of potentially harmful surfactants and 
excipients in the process of encapsulating hydrophobic drug molecules. Due to the fact that micelles 
can be specifically synthesized to increase a drug’s solubility and bioavailability, they are a model 
system for enhanced drug delivery [11–14]. 
Poly(ε-caprolactone) (PCL) having been widely used as the core-forming hydrophobic segment of 
nanoparticles was selected as the model polymer for this study. PCL is a semi-crystalline linear 
resorbable aliphatic polyester. It has been commonly used in drug delivery systems because it is 
biodegradable and biocompatible [15–17]. PCL is commonly synthesized by ring-opening polymerization 
of ε-caprolactone using an alcohol (R-OH) as an initiator and stannous (II) octoate (Sn(Oct)2) as a 
catalyst [18,19]. In addition to using R-OH as the initiator, methoxy-poly(ethylene oxide) and starch 
have been employed as macroinitiators to form amphiphilic polymers [20,21]. In this study, prodrug 
GCV possessing hydroxyl groups, was used as the initiator to obtain GCV-PCL. Then, hydrophilic 
chitosan was grafted on the hydrophobic GCV-PCL to form the amphiphilic block copolymer which 
already has the GCV prodrug attached started from the ring-opening polymerization. Chitosan is a 
natural polysaccharide derived from deacetylation of chitin. Chitosan’s biocompatible and biodegradable 
features have attracted much attention in biomedical and pharmaceutical research [15,21]. 
The synthesized GCV-tagged amphiphilic copolymer can be self-assembled in aqueous medium to 
form polymeric prodrug micelles, which can be used further to treat CMV infections. To this end, the 
chemical structure and physical properties of GCV-PCL-chitosan were characterized and polymeric 
prodrug micelle formation was investigated. Drug release of GCV from GCV-PCL-chitosan, as well as 
the biocompatibility of GCV-tagged polymeric micelles were examined. 
2. Results and Discussion 
2.1. Synthesis and Characterization of Amphiphilic Prodrug Polymers 
GCV-PCL was synthesized through ring-opening polymerization of ε-CL exclusively by GCV 
(Scheme 1A) using Sn(Oct)2 as a catalyst. While the mechanism of polymerization with Sn(Oct)2 is 
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still unclear, Sn(Oct)2 is not thought to be the actual initiator since polymer molecular weight does not 
depend on the monomer-to-Sn(Oct)2 molar ratio [18]. The most widely accepted mechanism for  
ring-opening polymerization is a coordination insertion mechanism where the hydroxyl functional 
group coordinates to Sn(Oct)2 forming the initiating tin-complex. To show the successful initiation of 
ε-CL by GCV, 1H-NMR analysis was conducted. The 1H-NMR spectra of prodrug GCV and GCV-PCL 
are shown in Figure 1i,ii, respectively. Chemical shifts at δ = 1.37 (j-CH2), 1.62 (i-CH2), 2.27 (h-CH2) 
and 4.04 (k-CH2) ppm correspond with the backbone chain of PCL polymer. Peaks at δ = 3.63 (f-CH2), 
5.47 (d-CH2) and 7.76 (b-CH) are assigned to protons in GCV. Evidence of GCV grafting to PCL is 
clearly seen by the characteristic resonances observed in the synthesized polymer, confirming the 
synthesis of GCV-PCL. 
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Scheme 1. Synthetic steps of (A) GCV-PCL, (B) GCV-PCL-COOH, (C) GCV-PCL-NHS, 
and (D) GCV-PCL-chitosan. 
GCV-PCL was further conjugated with chitosan as shown in Scheme 1B–D. Successful conjugation 
of chitosan was confirmed by analytical means. Figure 2 depicts the 1H-NMR analysis of chitosan (iii) 
and GCV-PCL-chitosan (iv). As shown in Scheme 1D, conjugation of chitosan to GCV-PCL was 
made via amide linkage. The peak at 1.79 (l-NH2) from a singlet to a multiplet in Figure 2iv confirms 
conjugation of chitosan to GCV-PCL. Moreover, the peaks from the protons on C3–C6 of chitosan can be 
seen from δ = 3.28–3.85, slightly shifted downward from the peaks shown in the original chitosan sample 
(Figure 2iii). Moreover, the gel permeation chromatography (GPC) data shown in Figure 3 confirmed 
the formation of amphiphilic copolymer GCV-PCL-chitosan. GCV-PCL hydrophobic polymer had an 
observed number-average molecular weight (Mn(obsd)) of 11.5 kDa which increased to 17.2 kDa after 
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the addition of chitosan. This corresponds well with the addition of chitosan which had an average 
molecular weight of 5 kDa. Furthermore, the polydispersity index (PDI) of both GCV-PCL and  
GCV-PCL-chitosan polymer was low at 1.13 and 1.18, respectively which indicate that the polymer chains 
are approaching a uniform chain length. The molecular weights of GCV-PCL and GCV-PCL-chitosan 
were found via GPC calibrated by polystyrene standards. The data were corrected via Mark-Houwink 
correction for Mn(corrected) = 0.56 × Mn(obsd) and the data are shown in Figure 3 [22,23]. 
 
Figure 1. 1H-NMR spectra of (i) GCV and (ii) GCV-PCL. 
 
Figure 2. 1H-NMR spectra of (iii) chitosan and (iv) GCV-PCL-chitosan. 
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Sample 
Mw 
(Da) 
Mn(obsd) a 
(Da) 
Mn(corrected) b 
(Da) 
Polydispersity 
(Mw/Mn(obsd)) 
GCV-PCL 12,996 11,454 6414 1.13 
GCV-PCL-chitosan 20,354 17,231 9649 1.18 
Notes: a Measured by GPC in THF relative to polystyrene standards; b Mn calculated after Mark-Houwink 
correction: Mn(corrected) = 0.56 × Mn(obsd). 
Figure 3. Characterization of molecular weight profiles of GCV-PCL (- - -) and  
GCV-PCL-chitosan (____) by GPC analysis. 
2.2. Formation and Characterization of GCV-Tagged Polymeric Micelles 
Through the solvent evaporation method, polymeric micelles of GCV-PCL-chitosan were formed. 
Here, the hydrophobic core segment was GCV-PCL and chitosan was the cationic and hydrophilic 
corona segment. The size of GCV-PCL-chitosan micelles was examined through dynamic light 
scattering (DLS) analysis. Figure 4A shows the size of GCV-tagged polymeric micelles. The average 
size as reported by DLS was 117 nm with a zeta potential of 24.2 mV (Figure 4B). The positive charge 
is attributed to chitosan used as the hydrophilic segment on the micellar carriers. To determine the drug 
loading percentage of GCV per mg of prepared micelle solution, the absorbance of GCV-PCL-chitosan 
was examined at t = 0 and t = 72 h and compared to a standard calibration curve of GCV ranging from 
0.002 to 1.0 mg·mL−1. It was found that GCV comprised 4.8% of the polymeric micelles. 
 
Figure 4. Physical characterization of GCV-PCL-chitosan micelles, (A) size analysis 
reported by DLS and (B) charge reported by zetasizer.  
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2.3. In Vitro Release of GCV from Polymeric Micelles 
The in vitro release behavior of GCV at 37 °C in PBS was examined. As can be seen from Figure 5, 
the release of GCV took 40 h to reach a maximum release of 77%. Moreover, there was an initial burst 
release within the first 2 h, followed by sustained release until 40 h. It is surmised that this burst 
release is due to the release of GCV which may already have weakened ester bonds between GCV and 
PCL. This is due to the fact that in order to bind chitosan to GCV-PCL-NHS, aqueous solvent is 
needed to dissolve chitosan, which can begin the breakage of ester bonds via hydrolysis. When 
conjugating GCV-PCL-NHS with methoxypolyethylene glycol amine (MPEG-NH2) in an organic 
solvent, the burst release of GCV from prepared GCV-PCL-MPEG micelles was not observed as the 
one shown in Figure 5 (data not shown). The release kinetics of GCV from GCV-PCL-chitosan was 
modeled using both power-law and Michaelis-Menten-type models. As can be seen from Figure 5, 
power-law model was not a good fit for the release of GCV from polymeric micelles. Here, the 
exponent, n, was equal to 0.29 in GCV-PCL-chitosan micelles. The exponent, n, of a sphere with 
Fickian diffusion as the drug release mechanism is 0.43 according to theoretical calculation [24]. 
Because our n value is lower than this value, the drug release mechanism of GCV from polymeric 
micelles is not solely through diffusion. Instead, the release of GCV from polymeric micelles was 
modulated by hydrolysis and diffusion. The ester bond must be first cleaved via hydrolysis and then 
GCV can diffuse out of the polymeric micelles. In contrast to the power-law model, the Michaelis-Menten 
model fits the release of GCV from polymeric micelles well because GCV release is driven by a 
reaction-diffusion mechanism. According to the Michaelis-Menten model, we found that the dissociation 
constant (Kd) was equal to 2.79 which is much higher than the release of ACV from ACV-PCL-chitosan 
polymeric micelles reported previously [25]. Such extended release of GCV from polymeric micelles 
probably is due to the relatively robust binding force between GCV-PCL generated by two hydroxyl 
groups existing on GCV, in comparison with only one hydroxyl moiety on ACV. 
 
Figure 5. In vitro drug release profile of GCV from GCV-PCL-chitosan in PBS at 37 °C 
(mean ± SD, n = 3). 
2.4. Cytotoxicity Test 
For a micelle carrier to be effective for any sort of drug delivery application, biocompatibility is 
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with various concentrations of GCV-tagged polymeric micelles ranging from 0–1 mg/mL. As can be 
seen in Figure 6A, MTT assay shows that the viability of HT29 cells after 48-h treatment with  
GCV-PCL-chitosan had little change when compared with the untreated cells (i.e., the control group). 
Moreover, cell images showed that micelle treatment at 1 mg/mL did not alter the growth morphology 
of HT29 cells (Figure 6C,E). Figure 6B–E showed that HT29 cells were still able to grow and 
proliferate after micelle treatment similar to the control group without any micelle challenge. These 
results demonstrate that GCV-PCL-chitosan micelles were non-toxic and biocompatible. 
In summary, we have shown that antiviral GCV can be used as the sole initiator in ring-opening 
polymerization of ε-CL, forming hydrophobic GCV-PCL. GCV-PCL can be further conjugated with 
chitosan for the formation of polymeric micelles. Polymeric micelles tagged with GCV have the drug 
attached to the polymer rather than housed in the core. Our results show that GCV-tagged polymeric 
micelles are biocompatible and have a small size for therapeutic use. 
 
Figure 6. Viability and morphology of HT29 colorectal cancer cells challenged with  
GCV-PCL-chitosan polymeric micelles at different dosages ranging from 0–1 mg/mL.  
(A) Viability of HT29 cells after 48 h treatment determined by MTT assay; (B) untreated cells, 
0 h; (C) micelle treated cells, 0 h; (D) untreated cells, 48 h; (E) micelle treated cells, 48 h. 
3. Experimental Section  
3.1. Materials 
GCV was purchased from Biotang Inc. (Lexington, MA, USA). N,N'-dicyclohexylcarbodiimide 
(DCC), ε-CL, pyrene, and succinic anhydride were purchased from Acros Organics (Geel, Belgium). 
Sn(Oct)2, CDCl3 with 1% tetramethylsilane (TMS), deuterated dimethyl sulfoxide (DMSO-d6), dimethyl 
sulfoxide (DMSO), tetrahydrofuran (THF), dichloromethane (DCM), methanol, 2-propanol, hexane, 
toluene, and chitosan oligosaccharide lactate (MW = 5000) were all purchased from Sigma-Aldrich 
(St. Louis, MO, USA). Ethyl ether was purchased from J.T. Baker (Austin, TX, USA).  
N-Hydroxysuccinimide (NHS) was purchased from Alfa Aesar (Ward Hill, MA, USA). Acetone was 
purchased from Pharmco-AAPER (Shelbyville, KY, USA). Pyridine and hydrochloric acid (HCl) were 
purchased from EMD (Philadelphia, PA, USA). Sodium chloride (NaCl) and magnesium sulfate were 
purchased from Showa (Tokyo, Japan). All reagents were used as received without further purification. 
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3.2. Characterization Methods 
Gel permeation chromatography (GPC) analyses were performed on a Waters 1525 binary HPLC 
pump equipped with a Waters 2414 refractive index detector (Milford, MA, USA). Waters styragel HR 
3 (MW = 500–30,000) and HR 4E (MW = 50–100,000) columns were equipped. Molecular weight 
calibration was performed with polystyrene standards that covered a MW range of 400–4.3 × 104. GPC 
analyses were performed in THF at a flow rate of 1 mL·min−1 with an injected volume of 50 µL.  
1H-NMR spectra were obtained from a Varian Unity/Inova 400 MHz instrument (Sparta, NJ, USA). 
3.3. Synthesis of GCV-Tagged Amphiphilic Polymers 
GCV (50 mg) was weighed and mixed with ε-CL (2.25 mL) under a sonication bath for 5 min at 
room temperature. Sn(Oct)2 (0.5 wt % of ε-CL) was then added into the mixture. The entire solution 
was placed into a 3-necked round-bottom flask. The system was purged with nitrogen and immersed in 
an oil bath at 140 °C for 24 h. The crude product was cooled to room temperature, dissolved in DCM, 
and precipitated by cold methanol. The product was then vacuum dried by a rotary evaporator at 40 °C. 
GCV-PCL (0.5 mmol) and succinic anhydride (1 mmol) were weighed and dissolved in toluene in a 
3-necked round-bottom flask. One mmol pyridine was added and the solution was reacted under 
nitrogen at 70 °C for 48 h. The product was then precipitated by cold hexane, and spun down. The 
pellet was re-dissolved in DCM and washed twice each with 10% (v/v) HCl and saturated NaCl 
solution. The organic phase was isolated and dried with magnesium sulfate then filtered. The 
carboxylated GCV-PCL was recovered by precipitation in cold hexane and then vacuum dried by 
rotary evaporation at 40 °C. 
GCV-PCL-COOH (0.54 mmol) and NHS (2.7 mmol) were weighed and mixed in 15 mL DCM, and 
then DCC (2.7 mmol) was added. The reaction was run under a nitrogen environment at room 
temperature for 24 h. The precipitated byproduct 1,3-dicyclohexylurea was removed by vacuum 
filtration. The filtrate was added into 35 mL diethyl ether and cooled to 4 °C for 4 h to precipitate 
GCV-PCL-NHS. The precipitate was collected by centrifugation at 3500 rpm for 5 min, washed with 
2-propanol and solvent removed by rotary evaporation at 40 °C. 
GCV-PCL-NHS (10 mg) was dissolved in 5 mL acetone and slowly added to chitosan solution  
(20 mg chitosan oligosaccharide lactate dissolved in 25 mL deionized water). The mixture, purged 
with nitrogen, was stirred in a round-bottom flask for 24 h. The reacted solution was vacuum dried to 
remove acetone and then lyophilized. The amphiphilic polymer was then dissolved in DCM and 
dialyzed (MWCO = 6–8 kD, Spectra/Por) against pure DCM to remove unreacted chitosan.  
GCV-PCL-chitosan was recovered by rotary evaporation at 40 °C. 
3.4. Preparation of Polymeric Prodrug Micelles 
10 mg of GCV-PCL-chitosan was dissolved in 2 mL acetone. The solution was then added 
dropwise to 10 mL deionized water under sonication. Acetone was removed by rotary evaporation and 
the final solution was collected by filtering through a 0.45 µm filter. 
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3.5. Size and Charge of Polymeric Prodrug Micelles 
The average particle size of polymeric prodrug micelles was determined by a dynamic light 
scattering (DLS) instrument (Zetasizer Nano ZS, Malvern Instruments, Westborough, MA, USA) 
equipped with a red laser at a wavelength of 633 nm and scattering angle of 90° at 25 °C. The zeta 
potential of the micelles dispersed in deionized water was determined with a zeta potential analyzer 
(Zetasizer Nano ZS).  
3.6. Drug Release Kinetics 
Polymeric prodrug micelles at a concentration of 1 mg·mL−1 were made in phosphate buffered 
saline (PBS) (1 M, pH 7.4) at 25 °C. Two mL of solution was placed in a dialysis tube (Float-A-Lyzer, 
Spectrum Labs, Rancho Dominguez, CA, USA) with a MWCO of 3.5–5 kD. The dialysis bag was then 
immersed in 50 mL PBS at 37 °C. At specified time intervals, 5 µL of sample was removed and 
replaced with fresh PBS. The amount of GCV released was analyzed by a plate reader (BioTek, 
Winooski, VT, USA) at 254 nm. All experiments were carried out in triplicate. 
3.7. Cytotoxicity Test 
24-well plates were seeded with human colorectal HT29 cells (HTB-38; ATCC, Manassas, VA, 
USA) suspended in 0.5 mL Dulbecco’s modified Eagles’ medium (DMEM, Corning Cellgro, 
Manassas, VA, USA) supplemented with 10% fetal bovine serum (FBS, Atlanta Biologicals, Flowery 
Branch, GA, USA) and 1% penicillin-streptomycin (Sigma) and incubated at 37 °C in 5% CO2 
balanced with humidified air for 24 h. In each well, 500 µL of 2 mg·mL−1 GCV-PCL-chitosan 
polymeric micelles (filtered by a 0.45 µm filter) was added. After incubation for 48 h, cell viability 
was assessed using MTT assay. 200 µL of sterile MTT solution in PBS (4 mg·mL−1) was added into 
the culture wells and incubated for 4 h. The medium containing unreacted MTT was removed and  
300 µL DMSO was added to dissolve the insoluble purple formazan crystals formed in cellular 
mitochondria. The absorbance at 590 nm was measured with a plate reader (BioTek) and results were 
recorded as viability percentage calculated against the control group without micellar challenge. All 
experiments were carried out in triplicate. 
4. Conclusions 
In conclusion, GCV-PCL-chitosan polymeric micelles were synthesized and characterized. Our 
results show that ring-opening polymerization of ε-CL can be initiated by guanosine-based prodrug 
GCV with Sn(Oct)2 as the catalyst. GCV-PCL can be easily produced compared to conventional 
methods, eliminating drug-loading steps, enhancing drug-carrying capacity, and decreasing production 
cost. Moreover, hydrophilic and cationic chitosan was grafted onto hydrophobic GCV-PCL for the 
formation of amphiphilic polymer micelles. 1H-NMR and GPC analysis confirmed the graft of 
chitosan to GCV-PCL. Size and zetasizer analysis showed that micelles in the range of 100 nm can be 
produced with a positive charge. Additionally, HT29 cells were challenged with GCV-PCL-chitosan  
polymeric micelles and showed no toxicity or inhibition of cell proliferation. This study shows that 
GCV-PCL-chitosan polymeric micelles are a potential carrier for antiviral drug therapy. 
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